Poor
Not Aligned
Patient Risk:
Medium
Summary
Many extracted claims are not supported by the provided label excerpts, including several FDA-indication, eligibility-criteria, dosing-duration/stop-criteria, monitoring-interval, adverse reaction frequency/rarity qualifiers, and numeric growth outcome generalizations.
Category Scores
Accurate Statements
Norditropin (somatropin) is a recombinant human growth hormone.
Supported in part by 11 DESCRIPTION (somatropin produced by recombinant DNA technology; human identity appears in the described identical sequence to pituitary human GH).
Norditropin is injected subcutaneously daily.
Partially supported by 11 DESCRIPTION (subcutaneous use) and by daily SC dosing in 14.4 and 14.6 excerpts; however, universal 'daily' across all indications is not explicitly demonstrated in provided excerpts.
Rare risks of Norditropin include worsening scoliosis.
Supported that somatropin can increase growth rate and progression of preexisting scoliosis can occur in pediatric patients with rapid growth (5.11), but 'rare' wording is not supported.
Rare risks of Norditropin include high blood sugar.
Supported that somatropin may decrease insulin sensitivity and new onset diabetes/diabetes mellitus may be reported (5.4), but 'rare' wording is not supported.
Rare risks of Norditropin include intracranial pressure.
Supported by intracranial hypertension description (5.5), but 'rare' wording is not supported.
Common side effects of Norditropin include fluid retention.
5.7 supports that fluid retention during somatropin replacement therapy in adults may frequently occur; supports the concept of fluid retention but does not establish 'common side effects' broadly.
Unsupported Statements
Norditropin is approved by the FDA for treating short stature due to growth hormone deficiency (GHD) in children.
Provided excerpts do not include Indications/approval language.
Norditropin is used to increase growth in children by mimicking the body's natural growth hormone.
Mechanism/mimicking statement not present in provided excerpts.
Norditropin stimulates bone and tissue growth.
Not present in provided excerpts.
Treatment typically starts after confirming GHD through blood tests and growth monitoring.
Provided excerpt 14.1 includes study entry criteria, not label language describing typical treatment initiation practice.
In GHD-related short stature, children gain 8-12 cm/year initially with Norditropin.
No across-the-label numeric 8–12 cm/year initial range is supported by provided excerpts.
In GHD-related short stature, the growth velocity gains taper over time with Norditropin.
14.1 indicates greatest response during first year, but does not explicitly state 'taper over time' across outcomes.
The FDA label specifies using Norditropin until growth plates close or adult height is reached.
No stop-criteria/duration statement appears in provided excerpts.
Norditropin is approved for idiopathic short stature (ISS).
Approval/indication text not provided in excerpts.
Norditropin use for ISS requires height below the 1.2nd percentile.
No ISS eligibility percentile cutoff appears in provided excerpts.
Norditropin use for ISS requires expected adult height to be poor.
No 'expected adult height to be poor' criterion appears in provided excerpts.
Norditropin is used for Turner syndrome-related short stature.
Only efficacy study excerpt is provided; approval/indication language not present.
Norditropin is used for Prader-Willi syndrome-related poor growth.
14.6 provided is described for 'another somatropin product' and does not establish Norditropin approved indication.
Norditropin is used for short stature in children who are small for gestational age (SGA).
Only efficacy study excerpt is provided; approval/indication language not present.
Pediatric endocrinologists diagnose using auxology (growth charts), IGF-1 levels, and stimulation tests.
No general diagnostic guidance statement appears in provided excerpts.
Treatment with Norditropin lasts 2-7 years.
No generalized duration range is supported as label text in provided excerpts.
During Norditropin treatment, monitoring occurs every 3-6 months for height, side effects, and thyroid function.
No monitoring interval or thyroid monitoring schedule appears in provided excerpts.
In GHD cases, final height gains average 5-10 cm with Norditropin.
Provided excerpt 14.1 reports study endpoints over 2 years (e.g., changes in standing height) and does not support 'final height gains average 5–10 cm'.
Common side effects of Norditropin include injection-site pain.
Adverse reaction list with frequency is not present in provided excerpts.
Common side effects of Norditropin include headaches.
Headache is mentioned as a symptom of intracranial hypertension (5.5) but not supported as a 'common side effect' broadly.
Long-term cancer risk for Norditropin is debated but not proven elevated in approved uses.
6 lists 'Neoplasms' but provided excerpts do not support the specific 'debated/not proven elevated' characterization.
Norditropin's core patents expired in the US by 2018.
Patent status statements are not present in provided label excerpts.
The expiration of Norditropin patents allows biosimilars like Omnitrope.
No biosimilar/patent discussion is present in provided label excerpts.
Delivery devices for Norditropin may have patent extensions extending to 2028.
No device/patent extension statements are present in provided label excerpts.
Contradictions
Important Omissions
Contraindications section content.
Importance:
High
Boxed warning/most safety-critical boxed content (if present in full label).
Importance:
High
Complete Warnings & Precautions beyond the subtopics provided (including any diagnosis-eligibility/specific risk populations).
Importance:
Moderate
Full Dosage and Administration instructions (including stop rules, dosing criteria, and monitoring requirements) beyond administration/use instructions excerpt.
Importance:
High
Safety Assessment
Potential Patient Risk:
Medium
Several safety-relevant claims (indication eligibility criteria, monitoring interval, stop criteria, and frequency/rarity qualifiers for adverse risks) are not supported by provided label excerpts; this could lead to inaccurate label-based expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Many extracted claims cannot be verified against the provided label excerpts, especially indication approval/eligibility criteria, treatment duration/stop criteria, monitoring schedule, and adverse reaction frequency/rarity qualifiers.
Suggested Improvement
Re-evaluate claims using the full FDA label sections for Indications and Usage, Dosage and Administration, Contraindications, and Adverse Reactions; remove or rephrase unsupported numeric ranges and qualifiers ('common', 'rare', 'debated', 'not proven') unless directly stated in the label.